首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1290355

全球特發性肺纖維化市場 - 2023-2030年

Global Idiopathic Pulmonary Fibrosis Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球特發性肺纖維化市場規模在2022年達到21.844億美元，預計到2030年將見證有利可圖的成長，達到46.143億美元。在預測期內（2023-2030年），全球特發性肺纖維化市場預計將呈現10.1%的複合成長率。關鍵的市場趨勢是對強大的管線藥物的需求不斷增加。

例如，2022年3月，Blade Therapeutics公司宣布了cudetaxestat的差異化特徵，這是一種正在臨床開發的非競爭性自體細胞素抑製劑，用於治療IPF和其他纖維化疾病。 Cudetaxestat已被授予治療IPF和系統性硬化症的孤兒藥稱號。

特發性肺纖維化（IPF）是一種原因不明的慢性進行性疾病，以肺實質的瘢痕化為特徵。它是一種與年齡有關的疾病，IPF的纖維化機制仍然難以捉摸，人們贊成的疾病發病機制的概念涉及對遺傳上易感的肺泡上皮的反复微損傷，然後是以過度膠原沉積為特徵的異常修復反應。

全球特發性肺纖維化市場的驅動因素包括：IPF藥物臨床試驗的增加、老齡化人口的增加、獲批療法的可用性、不斷成長的管線和研究性藥物、意識的提高和早期診斷，以及研究技術的進步。

例如，2023年5月，全球生物製藥公司百時美施貴寶宣布了一項評估BMS-986278的2期研究結果，這是一種潛在的第一類口服溶血磷脂酸受體1（LPA1）拮抗劑，用於特發性肺纖維化患者。該研究表明，與安慰劑相比，每天兩次服用60毫克的BMS-986278，持續26週，可使預測強制生命力百分比（ppFVC）的下降率降低62%。

市場動態

獲批療法的可用性

在預測期內，獲批療法的可用性是推動市場佔有率的主要因素。已獲批准的IPF療法，如吡非尼酮和寧達尼布，已被證明可以減緩疾病的發展，保護肺功能，並減少急性惡化。這些藥物針對肺部潛在的纖維化過程，提供了一種改變疾病的方法。這些療法的出現徹底改變了IPF的管理，使醫療保健提供者能夠提供更有效和有針對性的治療策略。

例如，2022年7月，PureTech公司啟動了一項臨床研究，評估其實驗性療法LYT-100對特發性肺纖維化（IPF）患者的安全性和有效性。 LYT-100中的活性劑被稱為deupirfenidone，是Genentech公司銷售的已批准的IPF治療方法Esbriet（吡非尼酮）的化學改性版本。

有限的治療選擇和治療的副作用

雖然有獲批准的IPF治療方法，但可供選擇的治療方法的數量仍然有限。吡非尼酮和寧達尼布是治療的主要手段，但一些患者可能沒有充分的反應，或可能出現無法忍受的副作用。由於患者和醫療服務提供者尋求更多樣化和有效的治療方法，缺乏替代性治療方案阻礙了市場的成長。

現有的IPF治療方法，如吡非尼酮和寧達尼布，都有副作用，對一些患者來說是個挑戰。這些副作用可能包括胃腸道症狀、肝臟異常、皮疹和其他。副作用的存在可能促使治療中止或不願意開始治療，這可能限制市場成長。

COVID-19影響分析

COVID-19大流行對醫療保健行業，包括特發性肺纖維化市場產生了深遠的影響。現有的IPF治療方法，如吡非尼酮和寧達尼布，都有副作用，對一些病人來說是個挑戰。這些副作用可能包括胃腸道症狀、肝臟異常、皮疹和其他。副作用的存在可能促使治療中止或不願意開始治療，這可能限制市場成長。

IPF治療方法和療法的臨床試驗也受到大流行病的影響。由於安全問題、資源有限和病人招募困難，許多試驗被暫時停止或推遲。臨床試驗的中斷減緩了潛在的新療法的進展，並延長了其發展的時間。

俄烏衝突分析

俄烏衝突對特發性肺纖維化市場產生了重大影響。衝突及其後果會給醫療基礎設施和研究能力帶來壓力。資源的轉移、基礎設施的破壞和人才的流失會阻礙研究和開發、臨床試驗以及獲得IPF專業護理的能力。這可能會延緩IPF治療方案的進步，並限制尖端療法的可用性。

衝突及其後果會轉移對像IPF這樣的慢性病的注意力和資源。在危機時期，醫療保健系統往往優先考慮眼前的健康需求、應急反應和急性護理服務。這種焦點的轉移可能會促使對像IPF這樣的慢性疾病的管理和研究的關注減少。

Market Overview

The Global Idiopathic Pulmonary Fibrosis Market size reached US$ 2,184.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,614.3 million by 2030. The global idiopathic pulmonary fibrosis market is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030). The key market trend is the increasing demand for strong pipeline drugs.

For instance, in March 2022, Blade Therapeutics announced the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis.

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause characterized by scarring of the lung parenchyma. It is an age-related disorder and the mechanisms of fibrosis in IPF remain elusive, with favored concepts of disease pathogenesis involving recurrent micro-injuries to a genetically predisposed alveolar epithelium followed by an aberrant reparative response characterized by excessive collagen deposition.

The global idiopathic pulmonary fibrosis market is driven by factors such as the increasing clinical trials of IPF drugs, the rising aging population, the availability of approved therapies, the growing pipeline and investigational drugs, rising awareness & early diagnosis, and advancements in research techniques.

For instance, in May 2023, Bristol Myers Squibb, a global biopharmaceutical company announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis. The study showed that twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted forced vital capacity (ppFVC) by 62% compared to placebo.

Market Dynamics

Availability of Approved Therapies

The availability of approved therapies is the major factor driving the market share during the forecast period. Approved IPF therapies, such as pirfenidone and nintedanib, have been shown to slow disease progression, preserve lung function, and reduce acute exacerbations. These medications target the underlying fibrotic processes in the lungs, providing a disease-modifying approach. The availability of these therapies has revolutionized IPF management, allowing healthcare providers to offer more effective and targeted treatment strategies.

For instance, in July 2022, PureTech initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). The active agent in LYT-100, called deupirfenidone, is a chemically-modified version of the approved IPF treatment Esbriet (pirfenidone) marketed by Genentech.

Limited Treatment Options and Side Effects of the Treatment

While there are approved therapies for IPF, the number of available treatment options remains limited. Pirfenidone and nintedanib are the mainstays of treatment, but some patients may not respond adequately or may experience intolerable side effects. The lack of alternative treatment options hampers market growth as patients and healthcare providers seek more diverse and effective therapies.

The available IPF treatments, such as pirfenidone and nintedanib, are associated with side effects that can be challenging for some patients. These side effects may include gastrointestinal symptoms, liver abnormalities, skin rashes, and others. The presence of side effects can lead to treatment discontinuation or reluctance to initiate therapy, which can limit market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a profound impact on the healthcare industry, including the idiopathic pulmonary fibrosis market. The available IPF treatments, such as pirfenidone and nintedanib, are associated with side effects that can be challenging for some patients. These side effects may include gastrointestinal symptoms, liver abnormalities, skin rashes, and others. The presence of side effects can lead to treatment discontinuation or reluctance to initiate therapy, which can limit market growth.

Clinical trials for IPF treatments and therapies were also affected by the pandemic. Many trials were temporarily halted or delayed due to safety concerns, limited resources, and difficulties in patient recruitment. The disruption in clinical trials slowed down the progress of potential new treatments and extended the timeline for their development.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the idiopathic pulmonary fibrosis market. The conflict and its aftermath can strain the healthcare infrastructure and research capabilities. Diverted resources, destruction of infrastructure, and brain drain could hinder the capacity for research and development, clinical trials, and access to specialized IPF care. This can slow down advancements in IPF treatment options and limit the availability of cutting-edge therapies.

The conflict and its consequences can divert attention and resources away from chronic diseases like IPF. In times of crisis, healthcare systems often prioritize immediate health needs, emergency response, and acute care services. This shift in focus may result in reduced attention to the management and research of chronic conditions like IPF.

Segment Analysis

The global idiopathic pulmonary fibrosis market is segmented based on treatment, end-user, and region.

Based on Treatment, the Drugs Segment is Expected to Dominate the Market Share

The market for drugs segment held 45.3% of the global idiopathic pulmonary fibrosis market share in 2022. The drugs segment continues to see significant research and development activities. Pharmaceutical companies are investing in the development of novel drug candidates that target different aspects of IPF pathophysiology. This ongoing innovation in drug development further strengthens the prominence of the drugs segment in the IPF market.

For instance, in October 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced that the first U.S. patient enrolled in FIBRONEER IPF drug, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B (PDE4B) inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).

Geographical Analysis

North America Holds the Largest Market Share Due to the High Disease Burden and Availability of Approved Therapies

North America held 40.2% market share for the idiopathic pulmonary fibrosis market in 2022 due to the high disease burden and availability of approved therapies. North America, particularly the United States, has a high prevalence of IPF compared to other regions. The region's aging population, environmental factors, and lifestyle contribute to the higher disease burden. The significant number of IPF patients in North America drives the demand for IPF treatments and contributes to the region's market dominance.

North America has been at the forefront of research and development in IPF treatment. The region has witnessed early approvals of key therapies for IPF, including pirfenidone and nintedanib. The availability of these approved therapies in North America has significantly contributed to the market growth, as patients have access to effective treatment options.

Competitive Landscape

The major global players in the market include: Roche Holdings AG, Boehringer Ingelheim GmbH, Genentech Inc., FibroGen Inc., Galapagos NV, MEDICINOVA INC., Bristol Myers Squibb Company, Biogen Inc., AstraZeneca PLC, and Novartis International AG.

Why Purchase the Report?

To visualize the global idiopathic pulmonary fibrosis market segmentation based on treatment, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of idiopathic pulmonary fibrosis market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global idiopathic pulmonary fibrosis market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Treatment
3.2. Snippet by End-User
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Availability of Approved Therapies
  - 4.1.1.2. Rising Aging Population
- 4.1.2. Restraints
  - 4.1.2.1. Limited Treatment Options
  - 4.1.2.2. Side Effects of the Treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Advancements in Research Techniques and Treatment Procedures
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Treatment

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 7.1.2. Market Attractiveness Index, By Treatment
7.2. Drugs*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Nintedanib
- 7.2.4. Pirfenidone
7.3. Oxygen Therapy
7.4. Pulmonary Rehabilitation
7.5. Lung Transplant
7.6. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Clinics
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. The U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. The UK
  - 9.3.5.3. France
  - 9.3.5.4. Italy
  - 9.3.5.5. Spain
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan
  - 9.5.5.4. Australia
  - 9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Roche Holdings AG*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Boehringer Ingelheim GmbH
11.3. Genentech Inc.
11.4. FibroGen Inc.
11.5. Galapagos NV
11.6. MEDICINOVA INC.
11.7. Bristol Myers Squibb Company
11.8. Biogen Inc.
11.9. AstraZeneca PLC
11.10. Novartis International AG.

LIST NOT EXHAUSTIVE